Study of three drugs for metastatic colorectal cancer
Part of Cancer clinical trials.
This trial tests a combination of three drugs (SHR-1701, SHR2554, and BP102) to see if they work better together for people with metastatic colorectal cancer. It is for those who have not been treated with similar immune checkpoint drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have metastatic colorectal cancer confirmed by biopsy.
- You are in good enough health to be up and about (ECOG 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your liver, kidney, blood clotting, and blood cell counts are within acceptable ranges.
- You agree to use birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug (HRS-2189) combined with two other medications (Adebrelimab and BP102) for people whose colorectal cancer has spread. It aims to see if this combination can help control the cancer.
This study tests a new drug called SHR-A1904 for people with advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this drug can help shrink or control the cancer.
This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.